A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

John W. Kitchens, Nawal Kassem, William Wood, Thomas W. Stone, Rick Isernhagen, Edward Wood, Brad A. Hancock, Milan Radovich, Josh Waymire, Lang Li, Bryan P. Schneider

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.

Original languageEnglish (US)
Pages (from-to)1987-1993
Number of pages7
JournalClinical Ophthalmology
Volume7
DOIs
StatePublished - Oct 9 2013

Keywords

  • Age related macular degeneration
  • ARMS2
  • Bevacizumab
  • Complement factor H (CFH)
  • LOC387715
  • Ranibizumab
  • Single nucleotide polymorphisms
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration'. Together they form a unique fingerprint.

Cite this